Truist Securities Reiterates Buy on CVS Health, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reiterated a Buy rating on CVS Health (NYSE:CVS) but lowered the price target from $90 to $66.

May 02, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities reaffirms a Buy rating on CVS Health but reduces the price target from $90 to $66.
The reduction in the price target by Truist Securities, despite maintaining a Buy rating, could lead to short-term negative sentiment among investors. This adjustment suggests that the analyst sees less upside potential than previously anticipated, which might impact investor confidence and potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100